CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research
SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.
Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goal of realizing breakthroughs in preclinical oncology strategies.
"Crown Biosciences recognizes the importance of supporting investigators in early discovery," said Laurie Heilmann, Chief Business Officer at Crown Bioscience. "By investing in the brightest scientific minds, we can evolve the current research paradigms and establish novel tools that will help researchers and drug developers address global health challenges."
For more details on the innovative grant program or to submit a proposal visit: Innovative Grant Program of Oncology Preclinical Early Discovery
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
LeddarTech and Cailabs Sign Collaboration Agreement on Combining LiDAR and Laser Beam Shaping Solutions for the Automotive Market19.12.2018 06:05 | Pressemelding
RENNES, France and QUEBEC CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- LeddarTech, an industry leader providing the most versatile and scalable automotive LiDAR development platform, announces that it has entered an agreement with Cailabs, a French deep tech company and global leader in light shaping technology, to explore combining LeddarTech’s solid-state LiDAR technology with Cailabs’ laser beam shaping solutions for the automotive industry. A memorandum of understanding between the two parties was signed on December 13, 2018. LeddarTech delivers a proprietary auto and mobility LiDAR platform based on the LeddarEngine™ (SoC + software) enabling high-performance, low-cost LiDAR sensor solutions and that is used by large Tier-1 suppliers to develop specific LiDARs for ADAS and autonomous driving applications. Cailabs develops and produces a unique range of optical components based on its know-how and its patented technological innovations, in particular, Multi-Plane Light Conversion (MPLC)
Industry-leaders join BIOPAC for T4 Human Physiology Conference Set for August 12-14, 201919.12.2018 01:34 | Pressemelding
Training and Best Practices for Measuring Physiology GOLETA, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- BIOPAC Systems, Inc., announced the second biennial T4 Human Physiology Conference to be held August 12-14, 2019 at the University of California Santa Barbara (UCSB). Life science researchers, educators, and students are invited to learn the latest Tools, Trends, Techniques, and Technology used in physiological measurement and interpretation. T4 sessions offer hands-on, practical tips and tricks, giving participants the latest tools and insights to pursue scientific discovery with significant amounts of data from multiple participants and devices, in or out of the lab. BIOPAC hosts the T4 Physiology Conference to increase understanding of physiological measurements. Frazer Findlay, BIOPAC CEO, says, “BIOPAC has always placed a strong emphasis on working with partners that understand the industry and the needs of our customers. I am delighted that we’ll have partners joining us at T4 t
RCI Banque S.A.: Post Stabilisation Notice18.12.2018 15:55 | Pressemelding
PARIS, Dec. 18, 2018 (GLOBE NEWSWIRE) -- 18th December 2018 RCI Banque S.A. Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken in relation to RCI Banque S.A. GBP Fixed due 30th Oct 2023 because the transaction did not complete. Issuer: RCI Banque S.A. Guarantor (if any): NA Aggregate nominal amount: GBP Benchmark Description: Fixed due 30th Oct 2023 Offer price: na Stabilising Managers: HSBC, Lloyds, Natwest This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and condit
The North American Bitcoin Conference Stands Out as One of 2019’s Most Important Worldwide Crypto Events18.12.2018 15:35 | Pressemelding
MIAMI, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire – 2019 will kick off with what has become widely accepted as one of the most important blockchain conferences of the year. The North American Bitcoin Conference, sponsored by Keynote and part of the World Blockchain Forum, will take place Jan. 16-18, 2019, at the James L. Knight Center in Miami, Florida. This premier crypto conference, now in its seventh year, will draw cryptocurrency and blockchain leaders from all across the globe as they come together for this historical event. The North American Bitcoin Conference is the longest-running, most-attended finance conference for the blockchain and crypto industries, with each event attracting thousands of attendees. The 2019 conference will feature a lineup of more than 60 world-class presenters, including technology veterans and company founders who have collectively raised more than $18.1 billion in initial coin offerings (ICOs). Speakers that have been announced thus far
Inspirata Subsidiary, Artificial Intelligence in Medicine (AIM), Signs Contract with the National Cancer Institute (NCI) to Use Its E-Path Reporter Software for Reporting by U.S. Central Cancer Registries18.12.2018 15:06 | Pressemelding
The NCI has licensed AIM’s E-Path Reporter software for the last 15 years to provide an automated solution that enables cancer registries to more efficiently collect and report cancer incidence and survival data. Toronto, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Artificial Intelligence In Medicine Inc. (AIM), an Inspirata company, announced today that the National Cancer Institute (NCI) has extended its license agreement for AIM’s E-Path Reporter software. The software has been licensed for use within the SEER (Surveillance, Epidemiology and End Results) program, for 14 central registries and 286 major reporting hospitals and laboratories across the U.S. NCI supports cancer data collection and research through the SEER program and publishes cancer statistics for 20 U.S. geographic areas. The NCI requires participating cancer registries to collect data on cancer patient demographics, primary tumor site, tumor morphology and disease stage at diagnosis. The registries also must report on fir
Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services18.12.2018 14:30 | Pressemelding
Services and Capacity Increase with New Site Opening SAN DIEGO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has recently announced the expansion of its existing translational oncology research capacity by opening a new site in Suzhou, Jiangsu, China. The large amount of data now available from preclinical and clinical research requires specialized expertise in bioinformatics, big data analysis and dedicated storage facilities. CrownBio’s new site will focus on integrating the company’s experience in preclinical and translational research with cutting-edge digital technologies for the discovery of predictive biomarkers and the development of new and companion diagnostics. The Suzhou site will become CrownBio’s center of excellence for systems biology and clinical sample testing. Located at the heart of the Bi